ViiV Healthcare, a specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, has received approval from the U.S. Food and Drug Administration (FDA) for Dovato (dolutegravir/lamivudine) for the treatment of HIV-1 infection in adolescents 12 years of age and older and weighing at least 25 kg with no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable ARV r...